

Nicotine Polacrilex

| | |
|----------------------------|---------------------------------|
| Type of Posting | Revision Bulletin, Postponement |
| Posting Date | 28–April–2017 |
| Official Date | 01–May–2017 |
| Expert Committee | Chemical Medicines Monographs 4 |
| Reason for Revision | Compliance |


In accordance with the Rules and Procedures of the 2015-2020 Council of Experts, the Chemical Medicines Monographs 4 Expert Committee has revised the Nicotine Polacrilex.

The purpose for the revision is to postpone the deletion of *Water Determination, Method I* (921) and the addition of *Loss on Drying* <731>. A future revision to use a flexible monograph approach using different procedures for glycerin containing and glycerin free Nicotine Polacrilex is being considered.

The Nicotine Polacrilex Revision Bulletin supersedes the monograph becoming official in *USP 40–NF 35*.

Should you have any questions, please contact Gerald Hsu, Ph.D., Senior Scientific Liaison, (240-221-3097 or gdh@usp.org)

Nicotine Polacrilex



$[(C_4H_6O_2)_x(C_{10}H_{10})_y](C_{10}H_{14}N_2)$
2-Propenoic acid, 2-methyl-, polymer with diethenylbenzene, complex with (S)-3-(1-methyl-2-pyrrolidinyl)pyridine;
Methacrylic acid polymer with divinylbenzene, complex with nicotine [96055-45-7].

DEFINITION

Change to read:

Nicotine Polacrilex is a weak carboxylic cation-exchange resin prepared from methacrylic acid and divinylbenzene, in complex with nicotine. It contains NLT 95.0% and NMT 115.0% of the labeled amount of nicotine ($C_{10}H_{14}N_2$), calculated on the **anhydrous** (RB 1-May-2017) basis.

▲[NOTE—Nicotine Polacrilex is also known as Nicotine Resinate.]▲^{USP40}

IDENTIFICATION

Change to read:

- **A. INFRARED ABSORPTION** ▲(197) **FOR NICOTINE:** [NOTE—Methods described in (197K) or (197A) may be used.]▲^{USP40}

Sample: Transfer an amount of Nicotine Polacrilex equivalent to 100 mg of nicotine to a 100-mL glass-stoppered tube. Add 20 mL of 1 M ammonium hydroxide, 5 mL of 10 M sodium hydroxide, and 20 mL of *n*-hexane. Shake for 5 min, and allow the phases to separate. Transfer the upper hexane phase to an evaporating dish, and evaporate on a steam bath.

Standard: Use USP Nicotine Bitartrate Dihydrate RS, and prepare as directed for the *Sample*.

Acceptance criteria: Meets the requirements

Change to read:

- **B. INFRARED ABSORPTION** ▲(197) **FOR POLACRILEX:** [NOTE—Methods described in (197K) or (197A) may be used.]▲^{USP40}

Standard: Transfer a portion of USP Polacrilex Resin RS, equivalent to the amount of Nicotine Polacrilex used to prepare the *Sample solution* in the *Assay*, to a glass-stoppered tube. Add 10 mL of 1 M ammonium hydroxide, shake for 10 min, then centrifuge. Decant the ammonia solution from the residue, and wash the residue by shaking it with three 10-mL volumes of water, decanting the water phase after each shaking. Wash with 10 mL of 0.1 N hydrochloric acid, decant the liquid, and dry the residue at 105°.

Sample: Use the residue obtained from the *Sample solution* in the *Assay*. Decant the ammonia solution remaining from the residue, and wash the residue by shaking it with three 10-mL volumes of water, de-

canting the water phase after each shaking. Wash with 10 mL of 0.1 N hydrochloric acid, decant the liquid, and dry the residue at 105°.

Acceptance criteria: Meets the requirements

- **C.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.

ASSAY

Change to read:

PROCEDURE

Solution A: Add 25 mL of 1 M acetic acid to 900 mL of water, then add 6 mL of ammonium hydroxide. Adjust with either 2 M acetic acid or 2 M ammonium hydroxide to a pH of 10.0, and dilute with water to 1000 mL.

Solution B: Acetonitrile

Mobile phase: See *Table 1*. ▲[NOTE—Re-equilibration time may be adjusted, if necessary.]

Table 1

| Time (min) | Solution A (%) | Solution B (%) |
|------------|----------------|----------------|
| 0 | 100 | 0 |
| 3 | 100 | 0 |
| 3.01 | 95 | 5 |
| 28 | 74 | 26 |
| 32 | 60 | 40 |
| 33 | 100 | 0 |
| 35 | 100 | 0 |

▲^{USP40}

System suitability solution: 1.5 mg/mL of USP Nicotine Bitartrate Dihydrate RS and 6 µg/mL of USP Nicotine Related Compound G RS in water

Standard solution: 1.8 mg/mL of USP Nicotine Bitartrate Dihydrate RS in water

Sample solution: Nominally 0.6 mg/mL of nicotine prepared as follows. Transfer an amount of Nicotine Polacrilex equivalent to 30 mg of nicotine to a glass-stoppered tube. Add 10.0 mL of 1 M ammonium hydroxide, shake vigorously for 10 min, then centrifuge. Transfer 5.0 mL of the clear solution to a 25-mL volumetric flask, add 5 mL of 1 M acetic acid, and dilute with water to volume. Retain the residue from centrifugation for use in *Identification B*.

Chromatographic system

(See *Chromatography* (621), *System Suitability*.)

Mode: LC

Detector: UV 254 nm

Column: 4.6-mm × 15-cm; 5-µm packing L1

Flow rate: 1.0 mL/min

Injection volume: 20 µL

System suitability

Samples: *System suitability solution* and *Standard solution*

[NOTE—See *Table 2* for the relative retention times.]

Suitability requirements

Resolution: NLT 2.5 between nicotine and nicotine related compound G, *System suitability solution*

Tailing factor: NMT 2.0 for nicotine, *System suitability solution*

Relative standard deviation: NMT 2.0%, *Standard solution*

2 Nicotine

Analysis

Samples: *Standard solution* and *Sample solution*
Calculate the percentage of the labeled amount of nicotine ($C_{10}H_{14}N_2$) in the portion of Nicotine Polacrilex taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

- r_U = peak response of nicotine from the *Sample solution*
 r_S = peak response of nicotine from the *Standard solution*
 C_S = concentration of USP Nicotine Bitartrate Dihydrate RS on the anhydrous basis in the *Standard solution* (mg/mL)
 C_U = nominal concentration of nicotine in the *Sample solution* (mg/mL)
 M_{r1} = molecular weight of nicotine, 162.23
 M_{r2} = molecular weight of anhydrous nicotine bitartrate, 462.41

Acceptance criteria: 95.0%–115.0% on the anhydrous (RB 1-May-2017) basis

IMPURITIES

• ORGANIC IMPURITIES

Solution A, Solution B, Mobile phase, Sample solution, and Chromatographic system: Proceed as directed in the *Assay*.

System suitability solution: 1.5 mg/mL of USP Nicotine Bitartrate Dihydrate RS and 6 µg/mL each of USP Nicotine Related Compound A RS, USP Nicotine Related Compound B RS, USP Nicotine Related Compound C RS, USP Nicotine Related Compound D RS, USP Nicotine Related Compound E RS, USP Nicotine Related Compound F RS, and USP Nicotine Related Compound G RS in water. [NOTE—The concentration of each related compound is in terms of the free base.]

Standard solution: 1.8 µg/mL of USP Nicotine Bitartrate Dihydrate RS in water

Sensitivity solution: 0.9 µg/mL of USP Nicotine Bitartrate Dihydrate RS in water from the *Standard solution*

System suitability

Samples: *System suitability solution*, *Standard solution*, and *Sensitivity solution*

[NOTE—See *Table 2* for the relative retention times.]

Suitability requirements

Resolution: NLT 2.5 between nicotine and nicotine related compound G, *System suitability solution*

Tailing factor: NMT 2.0 for nicotine, *System suitability solution*

Relative standard deviation: NMT 5.0%, *Standard solution*

Signal-to-noise ratio: NLT 10, *Sensitivity solution*

Analysis

Samples: *Sample solution* and *Standard solution*
Calculate the percentage of each impurity in the portion of Nicotine Polacrilex taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

- r_U = peak response of each impurity from the *Sample solution*
 r_S = peak response of nicotine from the *Standard solution*
 C_S = concentration of USP Nicotine Bitartrate Dihydrate RS on the anhydrous basis in the *Standard solution* (mg/mL)
 C_U = nominal concentration of nicotine in the *Sample solution* (mg/mL)
 M_{r1} = molecular weight of nicotine, 162.23
 M_{r2} = molecular weight of anhydrous nicotine bitartrate, 462.41

Acceptance criteria: See *Table 2*. Disregard peaks that are less than 0.05% of the nicotine peak.

Table 2

| Name | Relative Retention Time | Acceptance Criteria, NMT (%) |
|--------------------------------|-------------------------|------------------------------|
| Nicotine related compound E | 0.3 | 0.3 |
| Nicotine related compound C | 0.55 | 0.3 |
| Nicotine related compound F | 0.7 | 0.3 |
| Nicotine related compound A | 0.8 | 0.3 |
| Nicotine related compound D | 0.86 | 0.3 |
| Nicotine related compound G | 0.9 | 0.3 |
| Nicotine | 1.00 | — |
| Nicotine related compound B | 1.6 | 0.3 |
| Any other unspecified impurity | — | 0.10 |
| Total impurities | — | 0.8 |

SPECIFIC TESTS

Change to read:

• WATER DETERMINATION, *Method 1* (921)

Sample solution: Transfer about 1.0 g of Nicotine Polacrilex to a 50-mL glass-stoppered test tube, and add 20.0 mL of methanol. Shake for 30 min, and allow to stand for 30 min. Use a 10-mL portion of the methanol layer for the titration.

Acceptance criteria: NMT 5.0%

• (Deletion of the *Water Determination* test is postponed indefinitely.) (RB 1-May-2017)

Change to read:

▲ LOSS ON DRYING (731)

Analysis: Dry at 105° for 2 h.

Acceptance criteria: NMT 7.0%

• (Postponed indefinitely.) (RB 1-May-2017)

▲USP40

Change to read:

• NICOTINE RELEASE

Solution A: 9 mg/mL of sodium chloride in water

Sample stock solution: Transfer an amount of Nicotine Polacrilex equivalent to 4 mg of nicotine to a glass-stoppered tube, add 10.0 mL of *Solution A* that has been warmed to 37°, and shake by mechanical means for 10 min. Immediately pass the liquid through a dry filter paper, discarding the first mL of the filtrate.

Sample solution: Transfer 1.0 mL of the *Sample stock solution* to a 25-mL volumetric flask, and dilute with 0.1 N hydrochloric acid to volume.

Instrumental conditions

▲(See *Ultraviolet-Visible Spectroscopy* (857).)▲USP40

Mode: UV

Analytical wavelengths: 236, 259, and 282 nm

Blank: 1.0 mL of *Solution A* diluted with 0.1 N hydrochloric acid to 25 mL

Analysis

Samples: *Sample solution* and *Blank*

Calculate the percentage of nicotine released:

$$\text{Result} = (A_{259} - 0.5A_{236} - 0.5A_{282}) \times (V/E) \times (F/W) \times (1/P) \times 100$$

- A_{259} = absorbance of the *Sample solution*, corrected for the *Blank* absorbance, at a wavelength of 259 nm
 A_{236} = absorbance of the *Sample solution*, corrected for the *Blank* absorbance, at a wavelength of 236 nm
 A_{282} = absorbance of the *Sample solution*, corrected for the *Blank* absorbance, at a wavelength of 282 nm
 V = dilution volume, 250 mL
 E = specific absorbance of nicotine at a wavelength of 259 nm, $323 \text{ mL g}^{-1} \text{ cm}^{-1}$
 F = unit conversion factor, 1000 mg/g
 W = weight of Nicotine Polacrilex (mg)
 P = percentage of nicotine in Nicotine Polacrilex determined in the *Assay*
Acceptance criteria: NLT 70% in 10 min

ADDITIONAL REQUIREMENTS

Change to read:

- **PACKAGING AND STORAGE:** Preserve in tight containers, ▲protected from light.▲^{USP40}

Change to read:

- **USP REFERENCE STANDARDS (11)**
USP Nicotine Bitartrate Dihydrate RS
USP Nicotine Related Compound A RS
Anatabine;

- 1,2,3,6-Tetrahydro-2,3'-bipyridine.
 $C_{10}H_{12}N_2$ 160.22
USP Nicotine Related Compound B RS
Nicotyrine;
3-(1-Methyl-1*H*-pyrrol-2-yl)pyridine.
 $C_{10}H_{10}N_2$ 158.20
USP Nicotine Related Compound C RS
Cotinine;
(*S*)-1-Methyl-5-(pyridin-3-yl)pyrrolidin-2-one.
 $C_{10}H_{12}N_2O$ 176.22
USP Nicotine Related Compound D RS
Myosmine;
3-(4,5-Dihydro-3*H*-pyrrol-2-yl)pyridine fumarate.
 $C_9H_{10}N_2 \cdot C_4H_4O_4$ 262.26
USP Nicotine Related Compound E RS
Nicotine *N*-oxide;
(1*RS*,2*S*)-1-Methyl-2-(pyridin-3-yl)pyrrolidine 1-oxide oxalate.
 $C_{10}H_{14}N_2O \cdot C_2H_2O_4$ 268.27
USP Nicotine Related Compound F RS
Normicotine;
3-(Pyrrolidin-2-yl)pyridine.
 $C_9H_{12}N_2$ 148.20
USP Nicotine Related Compound G RS
Anabasine;
(*S*)-3-(Piperidin-2-yl)pyridine.
 $C_{10}H_{14}N_2$ 162.23
• USP Polacrilex Resin RS● (ERR 1-Jun-2016)